GSW promotes Deschamps to president and chief executive

GSW Worldwide has promoted Phil Deschamps from president to president and chief executive of the company.
This promotion recognizes Deschamps' expanded role in building and managing GSW Worldwide's global network in Europe and Asia, and in overseeing the agency's U.S. offices in Columbus and New York. He will continue to report to Blane Walter, chairman and chief executive of inChord, GSW Worldwide's parent company.
"In the past year, GSW Worldwide has become the largest independent global healthcare network in the world," said Walter. "Phil has been instrumental in expanding the network to include new offices and partnerships around the globe. He's also helped us create a completely unique model for working globally – one that is built around our clients' needs. In his new role as president and chief executive, Phil will oversee continued growth, while also partnering with our clients to ensure that their global marketing objectives are met."
Deschamps joined GSW Worldwide in 1998. Prior to his role as president, he was executive vice president overseeing Prozac and several other CNS accounts for the agency. Deschamps also played a key role in establishing GSW's presence in Europe in 2000. Before joining GSW, he spent 10 years in the marketing division at Bristol-Myers Squibb in Canada and Princeton, N.J., most recently as director of neuroscience marketing.
You must be a registered member of MMM to post a comment.

Next Article in Careers

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.